Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Seroquel Sustained Release (SR)
Seroquel Sustained Release · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Seroquel Sustained Release (SR) | DRUG | - |
| Seroquel Immediate Release (IR) | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * To be considered for this study the patients should be aged between 18 to 65 years, need to suffer from schizophrenia and must be willing to participate. Exclusion Criteria: * Patients that suffer from psychiatric disorders other than schizophrenia including drug abuse and d...
Seroquel Sustained Release is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for the treatment of schizophrenic disorder. It is a sustained release formulation studied in a Phase 3 registration trial. It is also known as Seroquel Sustained Release (SR).
Seroquel Sustained Release is being studied for the treatment of schizophrenic disorder. Its clinical development has focused on this psychiatric indication, with a Phase 3 registration study conducted in patients with schizophrenia. It is not described as approved for any use.
Seroquel Sustained Release is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 3 registration study of the sustained release formulation in schizophrenia.
Seroquel Sustained Release is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and has not been described as approved by the FDA.
Seroquel Sustained Release has been studied in one completed Phase 3 trial, NCT00206115, titled SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel in the Treatment of Patients With Schizophrenia. The randomized, double-blind study enrolled 535 patients across Bulgaria, Greece, India, Indonesia, the Philippines, Romania, Russia, and South Africa.
Yes. Seroquel Sustained Release and Seroquel SR refer to the same AstraZeneca product, with SR standing for sustained release. Both names describe the sustained release formulation studied in the Phase 3 schizophrenia program.